FDA Approves New Medication for Drug-Resistant HIV

Share this content:
FDA Approves New Medication for Drug-Resistant HIV
FDA Approves New Medication for Drug-Resistant HIV

TUESDAY, March 6, 2018 (HealthDay News) -- Trogarzo (ibalizumab-uiyk) has been approved by the U.S. Food and Drug Administration to treat adult patients living with HIV who have not responded to other antiretroviral medications.

Trogarzo is given intravenously once every 14 days in combination with other antiretroviral drugs, the FDA said Tuesday in a news release. The drug was evaluated in clinical studies involving 40 patients who continued to have high blood levels of HIV despite use of antiretroviral drugs. After 24 weeks of Trogarzo and other drugs, 43 percent of trial participants achieved HIV suppression, the FDA said.

The most common adverse reactions to Trogarzo were diarrhea, dizziness, nausea, and rash. More severe side effects included rash and immune reconstitution syndrome.

"While most patients living with HIV can be successfully treated using a combination of two or more antiretroviral drugs, a small percentage of patients who have taken many HIV drugs in the past have multidrug-resistant HIV, limiting their treatment options," Jeff Murray, M.D., deputy director of the FDA's Division of Antiviral Products, said in a statement. "Trogarzo is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options."

Trogarzo is produced by TaiMed Biologics, based in Taiwan.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Many Foster Kids Inappropriately Prescribed Psychiatric Drugs

Many Foster Kids Inappropriately Prescribed Psychiatric Drugs

Some children may be getting meds they don't need, others may be going without drugs that may help

FDA Approves Device for Acute Coronary Artery Perforations

FDA Approves Device for Acute Coronary Artery Perforations

The PK Papyrus device is a balloon-expandable covered coronary stent and delivery system

Decrease in Infant Walker-Related Injuries Since 2010

Decrease in Infant Walker-Related Injuries Since 2010

Decrease in injuries following implementation of federal mandatory safety standard in 2010

is free, fast, and customized just for you!




Already a member?

Sign In Now »